Oncos Therapeutics Ltd., a biotech company, develops cancer therapies based on oncolytic viruses. It designs and develops CGTG-102, an oncolytic adenovirus for the systemic stimulation of anti-tumor immune response, as well as to destroy metastases. The company was founded in 2007 and is based in Helsinki, Finland.
Tukholmankatu 8 A
Founded in 2007
Oncos Therapeutics Ltd. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 09:10 AM
Sep 28 14
Oncos Therapeutics Ltd. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 09:10 AM. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland.
Oncos Therapeutics Ltd. Presents at BIO-Europe 2014, Nov-05-2014 11:45 AM
Sep 3 14
Oncos Therapeutics Ltd. Presents at BIO-Europe 2014, Nov-05-2014 11:45 AM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.
Oncos Therapeutics Ltd. Appoints Dr. Magnus Jaderberg as Chief Medical Officer
Jun 4 14
Oncos Therapeutics Ltd. announced that it has appointed Dr. Magnus Jaderberg, M.D, Ph.D, as Chief Medical Officer (CMO). Dr. Jaderberg is a pharmaceutical physician with more than 25 years' experience in various R&D functions, including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management. His therapeutic area expertise includes immunology, oncology and infectious diseases. Dr. Jaderberg has experience of all phases of clinical research, including clinical pharmacology, dose finding, registration, post launch product differentiation and surveillance. His immunotherapy expertise includes Yervoy (ipilimumab), Enbrel (etanercept), Torisel (temsirolimus), Orencia (abatacept), Rapamune (sirolimus) and Nulojix (belatacept). Prior to joining Oncos Therapeutics, Dr. Jaderberg held senior position roles at national, European and global level at GlaxoSmithKline, Pharmacia, Wyeth and Bristol Myers Squibb (BMS). His most recent position was as Chief Medical Officer, at BMS Europe. Dr. Jaderberg joined Oncos Therapeutics on June 1, 2014.